J&J Building Case For Co-Administration Of Olysio With Gilead’s Sovaldi
This article was originally published in The Pink Sheet Daily
Executive Summary
Launched in the U.S. in 2013, Olysio brought in $354 million in worldwide sales during the first quarter, including $291 million in the U.S. Now, J&J will undertake a pair of Phase III trials that could back an sNDA to add co-administration with Sovaldi to the drug’s labeling.
You may also be interested in...
Emerging Markets Earnings Roundup: Roche, Johnson & Johnson (Part 1)
First quarter earnings by early birds Johnson & Johnson and Roche showed familiar currency headwinds in emerging markets and Japan.
How Sovaldi Won A Broad Label: Emerging Data Swayed Reluctant FDA
Agency reviewers were skeptical about awarding Gilead’s sofosbuvir an indication for use in combination with other, unspecified agents for treating chronic hepatitis C – a game-changing approach for the fast-evolving field. However, data submitted late in the review process from two ongoing Phase III studies convinced FDA that a broad indication was justified.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.